Коморбидность КОВИД-19 - ХОБЛ: характеристика и эволюция
DOI:
https://doi.org/10.52692/1857-0011.2024.2-79.46Ключевые слова:
КОВИД-19, ХОБЛ, коморбидность, SARS-CoV-2Аннотация
По данным исследований, ХОБЛ у лиц инфицированных SARS-CoV2, не является частой сопутствующей патологией. Частота выявления ХОБЛ среди сопутствующих заболеваний у пациентов с COVID-19 выявляется реже, чем в общей популяции. Однако ХОБЛ ухудшает течение коронавирусной инфекции, повышая риск неблагоприятных исходов заболевания и риск летального исхода. Коронавирусная инфекция у больных ХОБЛ протекает тяжелее по сравнению с другими сопутствующими заболеваниями и чаще приводит к госпитализации по сравнению с другими сопутствующими заболеваниями. ХОБЛ, являясь фактором риска тяжелого течения COVID-19, увеличивает вероятность повторных госпитализаций, переводов в отделения интенсивной терапии и увеличения смертности.
Библиографические ссылки
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. https://goldcopd.org/2024-gold-report/
WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. https://data.who.int/
Alqahtani, J.S., Oyelade, T., Aldhahir, A.M. et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020; 15 (5):
Zhang, X.Y., Huang, H.J., Zhuang, D.L., et al. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Infect Dis Poverty. 2020. 9(1). p.99.
Marcello, R.K., Dolle, J., Grami, S. et al. Characteristics and outcomes of COVID-19 patients in New York City’s Public Hospital System. PLoS One. 2020 Dec 17;15(12):e0243027.
Huang, Y., Tan, C., Wu, J., et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir. Res. 2020. 21(1). p. 163.
Beyerstedt, S., Casaro, E.B., Rangel, É.B. COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARSCoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40(5):905-919.
Saheb Sharif-Askari, N., Saheb, Sh. F., Alabed, M. et al. Airways expression of SARS-CoV-2 receptor, ACE- 2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Version 2. Mol. Ther. Methods Clin. Dev. 2020; 18: 1-6.
Zhou, P., Yang, X.L., Wang, X.G., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270-273.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 16:181(2): 271-280.
Huang, C., Wang, Y., Li, X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.
Li, G., Fan, Y., Lai, Y., et al. Coronavirus infections and immune responses. Journal of medical virology. 2020; 92(4):424-432. https://doi.org/10.1002/jmv.25685.
Leask, A. COVID-19: is fibrosis the killer? Journal of Cell Communication and Signaling. 2020;14(2):255.
Wang, B., Li, R., Lu, Z., et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020; 12 (7): 6049-6057.
Смирнова, М.И., Антипушина, Д.Н., Курехян, А.С. Хроническая обструктивная болезнь легких и COVID-19: данные к лету 2020 года, подходы к оказанию медицинской помощи и профилактике.Профилактическая медицина. 2020; 23(8):37-44.
Федеральные клинические рекомендации МЗ РФ “Хроническая обструктивная болезнь легких”, 2018. https://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf
Павленко, В.И., Кулик, Е.Г., Нарышкина, С.В. Хроническая обструктивная болезнь легких как коморбидное состояние при COVID-19. Амурский медицинский журнал, 2021, nr. 1, pp. 11-17.
Yin, T, Li, Y, Ying, Y, et al. Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors. BMC Infect Dis. 2021 Feb 22;21(1):200. doi: 10.1186/s12879- 021-05915-0.
Global Initiative for Chronic Obstructive Lung Disease. GOLD COVID-19 Guidance. Available at: GOLD COVID-19 Guidance Global Initiative for Chronic Obstructive Lung Disease GOLD (goldcopd.org).
Fang, X., Li, S., Yu, H., et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 2020. 12(13). P.12493-12503.
Yang, X., Yu, Y., Xu, J., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 8(5). P. 475-481. doi: 10.1016/S2213- 2600(20)30079-5.
Lupia, T., Scabini, S., Mornese, P.S. et al. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J. Glob. Antimicrob. Resist. 2020; 21: 22-27.
Goyal, P., Choi, J.J., Pinheiro, L.C. et al. Clinical characteristics of COVID-19 in New York city: Multicenter study. N. Engl. J. Med. 2020; 382 (24): 2372-2374.
Argenziano, M.G., Bruce, S.L., Slater, C.L. et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ, 2020, vol. 369: m1996.
Svist, P.G., Torchinsky, N.V., Briкo, N.I., et al. Prevalence of bronchial asthma and COPD in comorbidity with COVID-19. Epidemiology and Vaccinal Prevention. 2024; 23(1):66-76 (In Russ.).
Lippi, G., Henry, B.M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir. Med. 2020. 167. P.105941.
Shchikota, A.M., Pogonchenkova, I.V., Turova, E.A., et al. Chronic obstructive pulmonary disease and COVID-19: topical issues. Pulmonologiya. 2020; 30 (5): 599-608 (in Russian).
Zhao, Q., Meng, M., Kumar, R. et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J. Med. Virol. 2020; 92 (10):1915-1921.
Higham, A., Singh, D. Increased ACE2 expression in the bronchial epithelium of COPD patients who are overweight. Obesity (Silver Spring). 2020; 28 (9): 1586-1589.
Feng, Y., Ling, Y., Bai, T., et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020 Jun 1; 201(11):1380-1388.
Guan, W.J., Ni, Z. Y., Hu, Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 2020, Vol. 382, № 18. Р. 1708-1720.
Gerayeli, F.V., Milne, S., Cheung, C., et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. E Clinical Medicine. 2021; 33:100789.
Wu, F., Zhou, Y., Wang, Z., et al. Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: A multicenter, retrospective, observational study. J. Thorac. Dis. 2020;12(5):1811-1823.
Somani, S., Richter, F., Fuster, V., et al. Characterization of patients who return to hospital following discharge from hospitalization for COVID-19. medRxiv. 2020.
Docherty, A.B., Harrison, E.M., Green, C.A. et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020; 369: m1985.
Sheikh, D., Tripathi, N., Chandler, T.R., et al. Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non-SARS-CoV-2 community- acquired pneumonia. Respir. Med. 2022 an; 191: 106714.
Zaryanova, E.A., Osipova, G.L., Osipova, V.V. Chronic obstructive pulmonary disease and COVID-19. Pulmonologiya. 2022; 32 (5): 755-762 (in Russian).
Mehra, M.R., Desai, S.S., Kuy, S., et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N. Engl. J. Med., 2020; 382(25):e102.
Krayushkin, S.I., Ivakhnenko, I.V., Sushchuk, E.A., et al. Management of patients with chronic obstructive pulmonary disease in COVID 19 pandemic. Medical alphabet. 2020; (19): 77-80.
Samoylov, K.V., Bukreeva, E.B., Boyarko, V.V., et al. Features of COVID-19 in patients with chronic obstructive pulmonary disease, bronchial asthma, and cardiovascular comorbidity. The Siberian Journal of Clinical and Exp. Med. 2022; 37(4):63-69.
Cai, H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir. Med. 2020; 8 (4): e20. DOI: 10.1016/S2213-2600(20)30117-X.
Zhang, H., Tang, K., Fang, R., et al. What dermatologists could do to cope with the novel coronavirus (SARS-CoV-2): a dermatologist’s perspective from China. J. Eur. Acad. Dermatol. Venereol. 2020 May;34(5):e211-e212.
Condrațchi, D. Optimizarea expertizei medico-sociale în bronhopneumopatia obstructivă cronică. Rezumatul tezei de doctor în științe medicale. Chișinău, 2024. 31 p.
Moscovciuc, A., Simionica, I., Scaleţchi, V., Şincarenco, I. Bronhopneumopatia obstructivă cronica: interconexiunea genelor candidate ACE cu manifestări clinice de boală (sinteza de literatură). Bulletin of the Academy of Sciences of Moldova. Medical Sciences, 63(3), 271-275.
Emami, A., Javanmardi, F., Pirbonyeh, N., et al. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2020 Mar 24;8(1):e35.
Wu, Z., McGoogan, J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323 (13): 1239-1242.
Silva, A.B., Siqueira, S., et al. Long-COVID and Post- COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses. 2021 Apr 18;13(4):700.
World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_cond. (6 October 2021).
Загрузки
Опубликован
Лицензия
Copyright (c) 2025 Вестник Академии Наук Молдовы. Медицина
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
